Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEDI0457 + Durvalumab in HPV-Associated Cancers
NCT03439085Phase 2Terminated
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Nov 2018
- Primary completion
- Sep 2022
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of MEDI0457 in anal canal carcinoma (SCCA), cervical carcinoma, penile carcinoma, vaginal carcinoma, vulvar carcinoma, sponsored by University of Texas MD Anderson Cancer Center. Started Nov 2018; status: terminated.
02
Drugs
MEDI0457
03
Conditions
anal canal carcinoma (SCCA)cervical carcinomapenile carcinomavaginal carcinomavulvar carcinoma
Beyond the preview
Go deeper on NCT03439085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03439085.